Spinal Muscular Atrophy
Conditions
Keywords
Gene Transfer, Gene Therapy, Adeno-associated virus, Survival Motor Neuron, SMN, AAV9
Brief summary
The purpose of this trial is to evaluate the safety and tolerability of intrathecal administration of onasemnogene abeparvovec-xioi in infants and children with Spinal Muscular Atrophy with 3 copies of SMN2 and deletion of SMN1.
Detailed description
This is a Phase 1, single-dose administration study of infants and children with a genetic diagnosis consistent with spinal muscular atrophy (SMA), bi-allelic deletion of survival motor neuron 1 gene (SMN1) and 3 copies of survival motor neuron 2 gene (SMN2) without the genetic modifier who are able to sit but cannot stand or walk at the time of study entry. Patients will receive onasemnogene abeparvovec-xioi in a dose comparison safety study of two (or three) potential therapeutic doses. Patients will be stratified in two groups, those ≥6 months and \< 24 months of age at time of dosing and those ≥ 24 months and \< 60 months of age at time of dosing. At least 15 patients ≥ 6 months and \< 24 months, and at least 12 patients ≥ 24 \< 60 months will be enrolled. The first cohort will enroll three patients (Cohort 1) ≥ 6 months and \< 24 months of age who will receive administration of 6.0 × 1013 vg of onasemnogene abeparvovec-xioi (Dose A). There will be at least a four week interval between the dosing of each patient within the cohort. Novartis Gene Therapies, Inc. will confer with the Data Safety Monitoring Board (DSMB) on all Grade III or higher AEs within approximately 48 hours of awareness that are possibly, probably or definitely related to the study agent before continuing enrollment. Safety data will be reviewed by the DSMB during quarterly meetings; following enrollment of the three patients and based upon the available safety data a decision will be made whether to: a) stop due to toxicity, or b) proceed to Cohort 2 using Dose B. Should the determination be made to advance to Dose B, three patients \< 60 months of age will be enrolled (Cohort 2) and will receive administration of 1.2 × 1014 vg of onasemnogene abeparvovec-xioi (Dose B). Again, there will be at least a four-week interval between dosing of the three patients within the cohort. Based on the available safety data from the three Cohort 2 patients and all of the Cohort 1 patients, the DSMB will decide and document during quarterly meetings whether further four-week intervals between patients dosing is necessary. Novartis Gene Therapies, Inc. will take this recommendation into consideration and will make the final determination whether to persist with four-week intervals between patients dosing going forward; the decision will be communicated to sites and Institutional Review Boards (IRBs) in a formal sponsor letter. Novartis Gene Therapies, Inc. will confer with the DSMB on all Grade III or higher AEs within approximately 48 hours of awareness that are possibly, probably or definitely related to the study agent before continuing enrollment. Safety data will be reviewed by the DSMB during quarterly meetings; following enrollment of the first six patients and based upon available safety data, a decision will be made whether to: a) stop due to toxicity, or b) continue to enroll an additional 21 patients until there are a total of 12 patients \> 6 months and \< 24 months and 12 patients ≥ 24 and \< 60 months that have all received Dose B. Based upon an ongoing assessment of safety and efficacy data from patients treated with the 1.2 × 1014 vg dose, an option for testing of a third dose (Dose C), will be considered. If, based on all available data, this is judged to be safe and necessary, three patients \< 60 months of age will receive Dose C, 2.4 × 1014 vg administered IT. A meeting of the DSMB will be called to obtain a recommendation on the safety of escalating to a higher dose prior to proceeding. If a decision is made to proceed to testing a higher dose, there will again be a four-week interval between dosing of the first three patients receiving Dose C, as in Cohorts 1 and 2. Safety data will be reviewed by the DSMB during quarterly meetings. Following enrollment of the first three Dose C patients and based upon available safety data, the DSMB will be consulted and a decision will be made whether to: a) stop dosing Dose C due to safety concerns, or b) continue to enroll an additional 21 patients until there are a total of 12 patients \> 6 months and \< 24 months and 12 patients ≥ 24 and \< 60 months that have received Dose C. Patients from Cohort 3 will be followed for a total of 15 months post-dose. The primary analyses for efficacy will be assessed when all patients reach 12 months post-dose and the primary analyses for safety will be assessed when the last patient of Cohort 3 reaches 15 months post-dose (and database lock will be performed after the last patient reaches 15 months post-dose).
Interventions
BIOLOGICALOnasemnogene Abeparvovec-xioi
Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
Sponsors
Novartis Gene Therapies
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Months to 60 Months
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria * Patients ≥6 months and up to 60 months (1800 days) of age at time of dosing following diagnostic confirmation during screening period by genotype who demonstrate the ability to sit unassisted for 10 or more seconds but cannot stand or walk * Diagnostic confirmation by genotype includes lab documentation of homozygous absence of SMN1 exon 7; with exactly three copies of SMN2 * Negative gene testing for SMN2 gene modifier mutation (c.859G\>C) * Onset of clinical signs and symptoms consistent with spinal muscular atrophy (SMA) at \< 12 months of age * Able to sit independently and not standing or walking independently. Definition of sitting independently is defined by the World Health Organization Multicentre Growth Reference Study (WHO-MGRS) criteria of being able to sit up unsupported with head erect for at least 10 seconds. Child should not use arms or hands to balance body or support position (Wijnhoven 2004) * Be up-to-date on childhood vaccines that include palivizumab prophylaxis (also known as Synagis) to prevent respiratory syncytial virus (RSV) infections are also recommended in accordance with American Academy of Pediatrics (AAP 2009) Key
Exclusion criteria
* Current or historical ability to stand or walk independently * Contraindications for spinal tap procedure or administration of intrathecal therapy or presence of an implanted shunt for the drainage of CSF or an implanted central venous (CNS) catheter * Severe contractures as determined by designated Physical Therapist(s) at screening that interfere with either the ability to attain/demonstrate functional measures or interferes with ability to receive intrathecal (IT) dosing * Severe scoliosis (defined as ≥ 50° curvature of spine) evident on X-ray examination * Previous, planned or expected scoliosis repair surgery/procedure within 1 year of dose administration * Use of invasive ventilatory support (tracheotomy with positive pressure) or pulse oximetry \< 95% saturation at screening while the patient is awake, or for high altitudes \> 1000 m, oxygen saturation \< 92% while the patient is awake * Pulse oximetry saturation must not decrease ≥ four (4) percentage points between screening and highest value on day of dosing * Use or requirement of non-invasive ventilatory support for 12 or more hours daily over the two (2) weeks prior to dosing * Medical necessity for a gastric feeding tube, where the majority of feedings are given by non-oral methods (i.e., nasogastric tube or nasojejunal tube) or patients whose weight-for-age falls below the 3rd percentile based on WHO Child Growth Standards (Onis 2006). Placement of a permanent gastrostomy prior to screening is not an exclusion * Use or requirement of non-invasive ventilatory support for 12 or more hours daily over the two (2) weeks prior to dosing * Medical necessity for a gastric feeding tube, where the majority of feedings are given by non-oral methods or patients whose weight-for-age falls below the 3rd percentile based on WHO Child Growth Standards (Onis 2006). Placement of a permanent gastrostomy prior to screening is not an exclusion * Active viral infection (includes human immunodeficiency virus (HIV) or serology positive for hepatitis B or C, or Zika virus) * Serious non-respiratory tract illness requiring systemic treatment and/or hospitalization within two (2) weeks prior to study entry * Respiratory infection requiring medical attention, medical intervention or increase in supportive care of any manner within four (4) weeks prior to study entry * Severe non-pulmonary/respiratory tract infection within four (4) weeks before study dosing or concomitant illness that in the opinion of the Principal Investigator (PI) creates unnecessary risks for gene transfer such as: * Major renal or hepatic impairment * Known seizure disorder * Diabetes mellitus * Idiopathic hypocalciuria * Symptomatic cardiomyopathy * History of bacterial meningitis or brain or spinal cord disease, including tumors, or abnormalities by magnetic resonance imaging (MRI) or computerized tomography (CT) that would interfere with the lumbar puncture (LP) procedures or CSF circulation * Known allergy or hypersensitivity to prednisolone or other glucocorticosteroids or their excipients * Known allergy or hypersensitivity to iodine or iodine-containing products * Concomitant use of any of the following: drugs for treatment of myopathy or neuropathy, agents used to treat diabetes mellitus, or ongoing immunosuppressive therapy, plasmapheresis, immunomodulators such as adalimumab, or immunosuppressive therapy within 3 months of study dosing * Inability to withhold use of laxatives or diuretics in the 24 hours prior to dose administration * Anti-AAV9 antibody titers \>1:50 as determined by Enzyme-linked Immunosorbent Assay (ELISA) binding immunoassay * Should a potential patient demonstrate anti AAV9 antibody titer \> 1:50, he or she may receive retesting within 30 days of the screening period and will be eligible to participate if the anti AAV9 antibody titer upon retesting is ≤ 1:50 * Clinically significant abnormal laboratory values (GGT, ALT, and AST, or total bilirubin \> 2 × ULN, creatinine ≥ 1.0 mg/dL, hemoglobin \[Hgb\] \< 8 or \> 18 g/dL; white blood cell \[WBC\] \> 20,000 per cmm) prior to gene replacement therapy. Patients with an elevated bilirubin level that is unequivocally the result of neonatal jaundice shall not be excluded * Participation in recent SMA treatment clinical trial or receipt of an investigational or approved compound product or therapy received with the intent to treat SMA at any time prior to screening for this study * Oral beta agonists must be discontinued 30 days prior to dosing. * Inhaled albuterol specifically prescribed for the purposes of respiratory (bronchodilator) management is acceptable and not a contraindication at any time prior to screening for this study * Expectation of major surgical procedures during the 1-year study assessment period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Age 6 to <24 Months Only: Number of Participants Who Achieved the Ability to Stand Alone | From Day 1 up to Month 12 | Defined by the Bayley Scales of Infant and Toddler Development (BSID) Gross Motor (GM) subtest performance criteria number 40, confirmed by video recording, as a participant who stands alone for at least 3 seconds unsupported. |
| Age 24 to <60 Months Only: Change From Baseline in Hammersmith Functional Motor Scale-Expanded (HFMSE) Score at Month 12 | Baseline and Month 12 | The HFMSE contained 33 items which were scored on a scale of 0-2 with a total achievable score ranging from 0, if all activities are failed, to 66, if all the activities are achieved. A positive change from baseline indicates a better outcome. |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Adverse events were collected from the single dose of study treatment until the end of study visit (12 months for Cohort 1 and 2 and 15 months for Cohort 3) | A TEAE was defined as any event that began or worsened in severity on or after the administration of AVXS-101 through the last study visit. Evaluation of TEAEs included the number of participants with at least one: * TEAE * Serious TEAE * TEAE related to AVXS-101 * TEAE with Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 (grade 3 = severe or medically significant to grade 5 = death related to TEAE) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Achieved the Ability to Walk Alone | From Day 1 up to Month 12 | Defined by the BSID GM subtest performance criteria number 43, confirmed by video recording, as a participant who takes 5 coordinated independent steps. |
| Average Number of Hours Per Day of Non-invasive Ventilatory Support | Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 | Participants were assessed by a pulmonologist and may have been fitted with a non-invasive positive pressure ventilatory (e.g., Bilevel Positive Airway Pressure BiPAP) at the discretion of the pulmonologist and/or investigator. The number of hours per day of non-invasive ventilatory support was captured continuously by the device. |
Countries
United States
Participant flow
Recruitment details
A total of 32 participants took part in the trial at 11 sites in the United States between December 2017 and May 2021.
Pre-assignment details
A total of 38 participants were screened, of which 6 were screen failures and 32 were enrolled and received study drug.
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1: 6.0E13 Vector Genomes (vg) - Age 6 to <24 Months Participants aged 6 to \<24 months at time of AVXS-101 dosing received a single 6.0E13 vg dose of AVXS-101 administered as an intrathecal injection on Day 1 of the overall study. Participants also received daily doses of prophylactic oral prednisolone starting at a dose of 1 mg/kg/day from 1 day prior to AVXS-101 injection until at least 30 days post-injection at which point the prednisolone dose could be tapered downwards. At week 9, prednisolone could be discontinued. | 3 |
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months Participants aged 6 to \<24 months at time of AVXS-101 dosing received a single 1.2E14 vg dose of AVXS-101 administered as an intrathecal injection on Day 1 of the overall study. Participants also received daily doses of prophylactic oral prednisolone starting at a dose of 1 mg/kg/day from 1 day prior to AVXS-101 injection until at least 30 days post-injection at which point the prednisolone dose could be tapered downwards. At week 9, prednisolone could be discontinued. | 13 |
| Cohort 2: 1.2E14 vg - Age 24 to <60 Months Participants aged 24 to \<60 months at time of AVXS-101 dosing received a single 1.2E14 vg dose of AVXS-101 administered as an intrathecal injection on Day 1 of the overall study. Participants also received daily doses of prophylactic oral prednisolone starting at a dose of 1 mg/kg/day from 1 day prior to AVXS-101 injection until at least 30 days post-injection at which point the prednisolone dose could be tapered downwards. At week 9, prednisolone could be discontinued. | 12 |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months Participants aged 6 to \<24 months at time of AVXS-101 dosing received a single 2.4E14 vg dose of AVXS-101 administered as an intrathecal injection on Day 1 of the overall study. Participants also received daily doses of prophylactic oral prednisolone starting at a dose of 1 mg/kg/day from 1 day prior to AVXS-101 injection until at least 30 days post-injection at which point the prednisolone dose could be tapered downwards. At week 9, prednisolone could be discontinued. | 4 |
| Total | 32 |
Baseline characteristics
| Characteristic | Cohort 1: 6.0E13 Vector Genomes (vg) - Age 6 to <24 Months | Total | Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Cohort 2: 1.2E14 vg - Age 24 to <60 Months | Cohort 2: 1.2E14 vg - Age 6 to <24 Months |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 3 Participants | 32 Participants | 4 Participants | 12 Participants | 13 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Continuous | 17.2 months STANDARD_DEVIATION 4.1 | 24.6 months STANDARD_DEVIATION 12.5 | 16.9 months STANDARD_DEVIATION 5.6 | 37.5 months STANDARD_DEVIATION 10.6 | 16.7 months STANDARD_DEVIATION 4.5 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 5 Participants | 0 Participants | 0 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 1 Participants | 27 Participants | 4 Participants | 12 Participants | 10 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian | 0 Participants | 6 Participants | 1 Participants | 4 Participants | 1 Participants |
| Race/Ethnicity, Customized Multiple | 1 Participants | 2 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Other | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized White | 2 Participants | 23 Participants | 3 Participants | 8 Participants | 10 Participants |
| Sex: Female, Male Female | 2 Participants | 14 Participants | 0 Participants | 6 Participants | 6 Participants |
| Sex: Female, Male Male | 1 Participants | 18 Participants | 4 Participants | 6 Participants | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 0 / 13 | 0 / 12 | 0 / 4 |
| other Total, other adverse events | 3 / 3 | 13 / 13 | 12 / 12 | 4 / 4 |
| serious Total, serious adverse events | 1 / 3 | 2 / 13 | 4 / 12 | 0 / 4 |
Outcome results
Primary
Age 24 to <60 Months Only: Change From Baseline in Hammersmith Functional Motor Scale-Expanded (HFMSE) Score at Month 12
The HFMSE contained 33 items which were scored on a scale of 0-2 with a total achievable score ranging from 0, if all activities are failed, to 66, if all the activities are achieved. A positive change from baseline indicates a better outcome.
Time frame: Baseline and Month 12
Population: ITT Set: All enrolled participants who were given an AVXS-101 intrathecal injection. Participants were analyzed according to the assigned dose. Data were only collected in participants aged 24 to \<60 months at time of dosing.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Cohort 1: 6.0E13 Vector Genomes (vg) - Age 6 to <24 Months | Age 24 to <60 Months Only: Change From Baseline in Hammersmith Functional Motor Scale-Expanded (HFMSE) Score at Month 12 | 6.0 score on a scale |
p-value: 0.002795% CI: [1.9, 9]Mixed-Model Repeat Measure
Primary
Age 6 to <24 Months Only: Number of Participants Who Achieved the Ability to Stand Alone
Defined by the Bayley Scales of Infant and Toddler Development (BSID) Gross Motor (GM) subtest performance criteria number 40, confirmed by video recording, as a participant who stands alone for at least 3 seconds unsupported.
Time frame: From Day 1 up to Month 12
Population: Intent-to-Treat (ITT) Set: All enrolled participants who were given an AVXS-101 intrathecal injection. Participants were analyzed according to the assigned dose. Data were only collected in participants aged 6 to \<24 months at time of dosing.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1: 6.0E13 Vector Genomes (vg) - Age 6 to <24 Months | Age 6 to <24 Months Only: Number of Participants Who Achieved the Ability to Stand Alone | Able to Stand Alone | 1 Participants |
| Cohort 1: 6.0E13 Vector Genomes (vg) - Age 6 to <24 Months | Age 6 to <24 Months Only: Number of Participants Who Achieved the Ability to Stand Alone | Unable to Stand Alone | 2 Participants |
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Age 6 to <24 Months Only: Number of Participants Who Achieved the Ability to Stand Alone | Able to Stand Alone | 1 Participants |
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Age 6 to <24 Months Only: Number of Participants Who Achieved the Ability to Stand Alone | Unable to Stand Alone | 12 Participants |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Age 6 to <24 Months Only: Number of Participants Who Achieved the Ability to Stand Alone | Able to Stand Alone | 0 Participants |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Age 6 to <24 Months Only: Number of Participants Who Achieved the Ability to Stand Alone | Unable to Stand Alone | 4 Participants |
Comparison: Difference in the percentage of participants who achieved the ability to stand alone.p-value: >0.999995% CI: [-21.8, 22.8]Fisher Exact
Primary
Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
A TEAE was defined as any event that began or worsened in severity on or after the administration of AVXS-101 through the last study visit. Evaluation of TEAEs included the number of participants with at least one: * TEAE * Serious TEAE * TEAE related to AVXS-101 * TEAE with Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 (grade 3 = severe or medically significant to grade 5 = death related to TEAE)
Time frame: Adverse events were collected from the single dose of study treatment until the end of study visit (12 months for Cohort 1 and 2 and 15 months for Cohort 3)
Population: Safety Analysis Set: All participants given an AVXS-101 intrathecal injection. Participants were analyzed according to actual dose received.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1: 6.0E13 Vector Genomes (vg) - Age 6 to <24 Months | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAE with CTCAE Grade ≥ 3 | 1 Participants |
| Cohort 1: 6.0E13 Vector Genomes (vg) - Age 6 to <24 Months | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Serious TEAE | 1 Participants |
| Cohort 1: 6.0E13 Vector Genomes (vg) - Age 6 to <24 Months | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAE | 3 Participants |
| Cohort 1: 6.0E13 Vector Genomes (vg) - Age 6 to <24 Months | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAE Related to AVXS-101 | 0 Participants |
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Serious TEAE | 2 Participants |
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAE Related to AVXS-101 | 7 Participants |
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAE | 13 Participants |
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAE with CTCAE Grade ≥ 3 | 4 Participants |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAE | 12 Participants |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Serious TEAE | 4 Participants |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAE Related to AVXS-101 | 4 Participants |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAE with CTCAE Grade ≥ 3 | 4 Participants |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Serious TEAE | 0 Participants |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAE | 4 Participants |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAE with CTCAE Grade ≥ 3 | 0 Participants |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | TEAE Related to AVXS-101 | 1 Participants |
Secondary
Average Number of Hours Per Day of Non-invasive Ventilatory Support
Participants were assessed by a pulmonologist and may have been fitted with a non-invasive positive pressure ventilatory (e.g., Bilevel Positive Airway Pressure BiPAP) at the discretion of the pulmonologist and/or investigator. The number of hours per day of non-invasive ventilatory support was captured continuously by the device.
Time frame: Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
Population: Data were only collected in participants requiring BiPAP support.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 8 | 7.170 hours/day |
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 6 | 2.590 hours/day |
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 9 | 8.690 hours/day |
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 5 | 0.000 hours/day |
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 10 | 10.320 hours/day |
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 11 | 14.050 hours/day |
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 7 | 4.550 hours/day |
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 12 | 10.120 hours/day |
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 4 | 0.000 hours/day |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 11 | 3.460 hours/day |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 10 | 9.900 hours/day |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 12 | 0.040 hours/day |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 2 | 10.530 hours/day |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 3 | 2.930 hours/day |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 4 | 5.860 hours/day |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 5 | 4.610 hours/day |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 6 | 4.490 hours/day |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 7 | 7.490 hours/day |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 8 | 8.290 hours/day |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Average Number of Hours Per Day of Non-invasive Ventilatory Support | Month 9 | 7.690 hours/day |
Secondary
Number of Participants Who Achieved the Ability to Walk Alone
Defined by the BSID GM subtest performance criteria number 43, confirmed by video recording, as a participant who takes 5 coordinated independent steps.
Time frame: From Day 1 up to Month 12
Population: ITT Set: All enrolled participants who were given an AVXS-101 intrathecal injection. Participants were analyzed according to the assigned dose.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1: 6.0E13 Vector Genomes (vg) - Age 6 to <24 Months | Number of Participants Who Achieved the Ability to Walk Alone | Able to Walk Alone | 0 Participants |
| Cohort 1: 6.0E13 Vector Genomes (vg) - Age 6 to <24 Months | Number of Participants Who Achieved the Ability to Walk Alone | Unable to Walk Alone | 3 Participants |
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Number of Participants Who Achieved the Ability to Walk Alone | Unable to Walk Alone | 12 Participants |
| Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Number of Participants Who Achieved the Ability to Walk Alone | Able to Walk Alone | 1 Participants |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Number of Participants Who Achieved the Ability to Walk Alone | Able to Walk Alone | 0 Participants |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Number of Participants Who Achieved the Ability to Walk Alone | Unable to Walk Alone | 12 Participants |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Number of Participants Who Achieved the Ability to Walk Alone | Able to Walk Alone | 0 Participants |
| Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Number of Participants Who Achieved the Ability to Walk Alone | Unable to Walk Alone | 4 Participants |
Comparison: Difference in the percentage of participants who achieved the ability to walk alone.p-value: >0.999995% CI: [-17.2, 27]Fisher Exact